产品
编 号：F715398
分子式：C24H21ClF3N5O
分子量：487.9
分子式：C24H21ClF3N5O
分子量：487.9
产品类型
规格
价格
是否有货
结构图
CAS No: 2379727-90-7
产品详情
生物活性：
Antitumor agent-19 is an antitomor agent targeting tumor-associated macrophages (TAMs) to serve as an effective TAMs modulator. The EC50 values of Antitumor agent-19 in the RAW 264.7 cells and the BMDM cells are 17.18 μM and 18.87 μM, respectively.
体内研究：
Antitumor agent-19 (Compound 23a; 5 mg/kg; intraperitoneal injection; every other day; for 30 days; C57BL/6 female mice) is capable of remarkably inhibiting tumor growth of the LLC mouse model. Moreover, the synergy of Antitumor agent-19 with anti-PD-1 antibody has more superior antineoplastic effects than the exclusive use of either in vivo.Animal Model:Six-to eight-week-old C57BL/6 female mice with lewis lung cancer cells (LLC)
Dosage:5 mg/kg
Administration:Intraperitoneal injection; every other day; for 30 days
Result:Remarkably inhibited tumor growth of the LLC mouse model.
体外研究：
Antitumor agent-19 (Compound 23a; 10-50 μM; 1 hour; RAW 264.7 cells) treatment effectively induces the expression of M1-phenotype macrophage markers (IL-1β, TNF-α, iNOS and IL-12α) in a dose-dependent manner. Antitumor agent-19 is found to dose-dependently repolarize TAMs from M1 (anti-tumor) and M2 (pro-tumor).
Antitumor agent-19 is an antitomor agent targeting tumor-associated macrophages (TAMs) to serve as an effective TAMs modulator. The EC50 values of Antitumor agent-19 in the RAW 264.7 cells and the BMDM cells are 17.18 μM and 18.87 μM, respectively.
体内研究：
Antitumor agent-19 (Compound 23a; 5 mg/kg; intraperitoneal injection; every other day; for 30 days; C57BL/6 female mice) is capable of remarkably inhibiting tumor growth of the LLC mouse model. Moreover, the synergy of Antitumor agent-19 with anti-PD-1 antibody has more superior antineoplastic effects than the exclusive use of either in vivo.Animal Model:Six-to eight-week-old C57BL/6 female mice with lewis lung cancer cells (LLC)
Dosage:5 mg/kg
Administration:Intraperitoneal injection; every other day; for 30 days
Result:Remarkably inhibited tumor growth of the LLC mouse model.
体外研究：
Antitumor agent-19 (Compound 23a; 10-50 μM; 1 hour; RAW 264.7 cells) treatment effectively induces the expression of M1-phenotype macrophage markers (IL-1β, TNF-α, iNOS and IL-12α) in a dose-dependent manner. Antitumor agent-19 is found to dose-dependently repolarize TAMs from M1 (anti-tumor) and M2 (pro-tumor).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备